CompanyGraph
Blood can travel from donor to patient in hours, but it must be separated, tested, stored, matched, and identified without losing either function or identity.
How a donation becomes a transfusion
The transfusion chain begins with a person, not a factory. Before collection, staff assess whether donation is suitable for the donor and the eventual recipient. Whole blood may be drawn into a sterile bag containing anticoagulant and preservative, while an apheresis machine can collect a selected component and return the remainder to the donor. Tubes taken at the same time carry samples for testing. The donation and samples receive an identifier that must keep them connected.
A blood service transports the donation to processing. Centrifugation and expression into connected bags can separate whole blood into red cells, plasma, and sometimes platelets. Depending on the component and intended patient, further work may include removing many white cells, irradiation, washing, pooling, or pathogen reduction. Testing establishes the ABO and Rh group and screens for specified transfusion-transmissible infections. Until required results are complete, the component remains unavailable for routine issue.
Released components enter different storage environments. Red cells are refrigerated, most conventional platelets are held at controlled room temperature with agitation, and plasma can be frozen. A hospital orders what it expects to use and receives it by validated transport. Its transfusion service stores the component, tests a patient sample, selects a suitable unit, and performs the required compatibility procedure. At the bedside, staff must connect the intended patient to the sample, order, label, component, and prescription before starting the transfusion.
The chain continues during and after administration. Staff observe the patient, stop and investigate suspected reactions, record the disposition of the component, and report defined events. Some donated plasma follows a different chain into industrial fractionation and plasma-derived medicines; this article follows components intended for transfusion.
What does the patient actually need?
A patient does not need "blood" as an undifferentiated commodity. The needed intervention depends on which physical function the patient's body cannot maintain quickly enough.
Red cells contain haemoglobin and increase oxygen-carrying capacity. Platelets support haemostasis, the process that stops bleeding. Plasma contains proteins including coagulation factors, while cryoprecipitate concentrates a smaller set of proteins such as fibrinogen. Whole blood can supply red cells and volume with variable contributions from plasma factors and platelets, and is used in defined settings such as severe bleeding. The 2024 Circular of Information, prepared by US blood organizations and recognized by the FDA, distinguishes these actions, indications, limitations, and hazards component by component.
The biological need may follow acute haemorrhage, impaired blood-cell production, destruction of cells, deficient or dysfunctional platelets, or clinically significant coagulation problems. In some situations transfusion is the fastest or only available way to restore a critical function. In others, the underlying condition can be treated without donor blood or with less of it.
That distinction matters because current transfusion demand is not fixed entirely by disease and injury. The World Health Organization's 2025 patient blood management guidance starts with the patient: prevent and treat anaemia, reduce blood loss, manage coagulation, use blood conservation and salvage where appropriate, and transfuse when clinically indicated. These actions do not declare necessary transfusions unnecessary. They prevent the chain from treating every low laboratory value or expected surgical loss as an automatic order for a donated component.
Why does demand differ between health systems?
Trauma, obstetric haemorrhage, cancer treatment, inherited blood disorders, and major surgery create genuine needs in every region. Their mix differs, and so does the surrounding ability to prevent blood loss, diagnose the cause, treat it early, and deliver an alternative. A system with access to iron therapy, medicines, cell salvage, careful surgical technique, and rapid laboratory support can face a different component requirement from one treating the same underlying condition without those means.
Clinical organization also changes when demand appears. Elective procedures can be coordinated with inventory and a patient's blood condition; emergencies cannot. Repeated diagnostic sampling can contribute to anaemia in vulnerable patients. A component ordered "just in case" may be unavailable for another patient until it is returned, and may be discarded if storage or traceability requirements were broken. None of these outcomes is explained by patient biology alone.
Access differs even before a clinician makes a decision. The WHO's 2026 blood safety and availability fact sheet, based mainly on 2023 country data, reports about 120.4 million donations worldwide. High-income countries, with 15% of the world's population, collected 36% of them. Donation rates, component-processing capacity, quality systems, transport, and hospital access all vary. A patient can therefore lack a suitable transfusion because the biological material was never collected, because the system could not process it into the needed component, or because it could not reach the patient in time.
Money shapes these physical possibilities even when the donor is unpaid. Collection requires trained staff, safe sites, sterile sets, testing reagents, centrifuges, refrigerators, platelet incubators, backup power, information systems, vehicles, and hospital laboratories. The WHO reported in 2026 that more than one in seven countries had neither a dedicated government budget nor a cost-recovery mechanism for blood services. The shortage in such a setting is not evidence that people chose not to organize safely; the equipment and continuous work require material support.
What constrains collection and preparation?
Donation removes cells or plasma from a living person, who must remain safe and recover. Eligibility questions, haemoglobin checks, collection intervals, observation, and care therefore protect the donor as well as the recipient. Deferral does not mean the person's blood has no biological usefulness; it means the donation does not meet the service's defined conditions at that time.
Nor does every country use one donor relationship. WHO distinguishes voluntary unpaid donors, family or replacement donors, and paid donors. Its 2026 data show that voluntary unpaid donations supplied more than 85% of the estimated global total in 2023, but 59 countries still obtained more than half of their supply from family/replacement or paid donors. A chain built on regular voluntary donation, one requiring a patient's family to replace units, and one collecting paid source plasma place different demands on people and produce different information and access pressures.
A blood service cannot order red cells from a factory, but it can change which collection opportunities exist. It can recruit regular donors, contact donors with needed groups or antigen profiles, place mobile teams, extend appointments, or collect a selected component by apheresis. Each action needs eligible people, staff, equipment, time, and testing capacity. A public appeal that produces more donations than can be processed or used before expiry has not necessarily improved the complete process.
Component preparation also changes what one donation can do. Separating whole blood allows different patients to receive the function they need. Apheresis can collect platelets or plasma more directly and can help target supply, but it requires specialised machinery and more donor time. According to WHO data, the proportion of collected blood separated into components in 2023 ranged from 52% in low-income countries to 98% in high-income countries. Component availability is therefore partly a property of processing infrastructure, not just donor numbers.
Why can a full refrigerator still represent a shortage?
Blood inventory is not one count. It is divided by component, storage history, ABO group, Rh type, additional antigens or antibodies, intended use, location, and time remaining within validated storage.
Under common US specifications, additive-solution red cells may be stored at 1–6 °C for up to 42 days. Conventional platelet products generally have much shorter dating, commonly five to seven days under approved bacterial-control strategies, because room-temperature storage supports platelet function but also permits bacterial growth. Frozen plasma may retain a one-year dating period under specified conditions. These are product and jurisdiction examples, not universal biological clocks. Processing method, container system, temperature, opening a closed system, thawing, and local authorization can shorten or alter them.
An expiry date is also not a claim that function remains perfectly unchanged until midnight and disappears one minute later. It is the end of a validated set of conditions. Before issue, the service must still inspect the component and confirm that storage and handling remained within requirements. The FDA notes the particular bacterial hazard created by room-temperature platelet storage; testing or pathogen reduction reduces a defined hazard without turning platelets into a long-lived stock item.
Compatibility divides inventory further. Red-cell-containing components must be ABO compatible, and patient antibodies can require selection beyond ABO and Rh. In a life-threatening emergency, uncrossmatched group O red cells or group-specific red cells may be issued before normal compatibility work is complete under defined procedures. That emergency option moves risk; it does not make every unit interchangeable. Platelets and plasma follow different compatibility considerations.
Some rare red-cell units can be frozen for longer storage, but freezing, specialised storage, thawing, washing, and the shortened post-thaw period require infrastructure and time. Frozen rare units are a targeted reserve, not evidence that routine red-cell or platelet demand can be stockpiled indefinitely.
A hospital may consequently have many units and still lack the component suitable for one patient. Another hospital may hold the match, but transferring it consumes time, validated packaging, staff coordination, transport ability, and some of the remaining storage period.
What can the chain verify?
Availability is a material question; verification is an evidentiary one. Safety depends on several observations, each answering a different question. Donor screening addresses health and exposures under current rules. Laboratory screening looks for specified infection markers. Blood grouping identifies selected antigens and antibodies. The component label carries identity, preparation, storage, expiry, group, and other attributes. Pretransfusion testing connects a patient sample to a compatible component; the bedside check connects that component to the actual patient.
The FDA requires US establishments to test each donation for relevant transfusion-transmitted infections or use an appropriate pathogen-reduction process for certain infections. Its blood donation testing summary requires the component to remain quarantined until required testing is complete. A negative result supports release against the agents and detection methods in scope. Temperature history, patient compatibility, and agents outside or below those methods require other evidence.
The label is unusually rich because identity must survive every handoff. The 2024 Circular lists the unit or pool identification number, component and preparation method, storage temperature, expiry, collection and processing establishment, donor category, ABO and Rh information where applicable, and special handling instructions. This makes a unit locatable for issue, recall, or investigation and can connect a recipient to a donation. Its usefulness still depends on correct sampling, entry, attachment, scanning, and handling.
A 2024 CDC-authored analysis provides concrete evidence about where that connection can fail. Eighty participating US acute-care facilities reported 63,900 transfusion-related errors to a voluntary surveillance module for 2014–2022. More than half occurred during patient blood-sample collection or sample handling. Because reporting was voluntary and limited to participating facilities, the study cannot yield a national error rate. It does show the mechanism: a correctly manufactured and tested unit can become unsafe if the patient sample or its identity is wrong.
Barcodes and electronic matching can intercept defined discrepancies when correct identifiers were attached and the system is used as designed. Temperature excursions, mistyped samples, and clinical necessity lie outside what the scan observes.
What can each participant actually change?
Verification does not make corrective action available. Each participant controls a different part of the chain. The donor provides information, attends, and consents. Collection staff protect the donor and preserve the donation's initial identity and condition. The blood service tests, processes, labels, stores, recruits, forecasts, and redistributes. Couriers preserve transport conditions. The hospital transfusion service manages stock and compatibility work. Clinicians decide whether a component is indicated; bedside staff make the final identity connection and observe the patient.
Each action requires more than knowledge. A service cannot add platelet appointments without machines, disposables, trained operators, eligible donors, and laboratory throughput. A rural hospital cannot hold every rare match; it needs transport and a reachable regional network. A clinician cannot use cell salvage where no suitable equipment or team exists. A transfusion service cannot recover a unit whose temperature history is unknown merely because demand is urgent.
Measurements can pull action in conflicting directions. Blood services count collections, released components, expiry, test turnaround, and deliveries; hospitals count crossmatched-to-transfused ratios, reactions, and discarded units. Holding less inventory can reduce expiry while making an urgent match more likely to be absent. Holding more preserves readiness while increasing discard. Judging either result requires the patient need, storage boundary, transfer options, and time period.
The preferable action must be feasible before the emergency. Preventing and treating anaemia, maintaining collection sites, validating equipment, training staff, sharing inventory, and operating haemovigilance all require money and work in advance. An appeal after a shortage is visible cannot instantly produce tested red cells or platelets at the bedside.
When does a failure become visible?
Which actions remain possible depends on when the problem is found. Before transfusion, a reactive donor test, damaged bag, abnormal appearance, expired label, temperature deviation, patient-sample discrepancy, or electronic mismatch can be intercepted. The component may be quarantined, investigated, relabelled where allowed, returned, or discarded, while the patient still needs another suitable unit.
Other problems become visible only during or after transfusion. Fever, breathing difficulty, low blood pressure, haemolysis, circulatory overload, infection, or a poor platelet response can have different causes. Stopping the transfusion protects the patient from further exposure but cannot retrieve material already infused. The investigation must connect symptoms, patient condition, unit identity, compatibility work, processing, storage, and donor information without assuming that temporal association proves cause.
Haemovigilance turns individual events into feedback. WHO defines it as monitoring, reporting, investigating, and analysing adverse events across donation, processing, and transfusion, followed by action to prevent recurrence. Its national haemovigilance guide emphasizes that this work belongs throughout the chain, not only at the bedside.
Haemovigilance produces a record; correction requires the unit identifier to lead to the affected donation and related components, then carry the finding to the participant able to change the cause. Surveillance also depends on participation and reporting. An absent report may mean no event occurred, or that the event was not recognized, connected, or submitted.
Who is responsible for the complete transfusion?
The final question is whether observation, authority, and correction stay connected across organizations. No single organization needs to recruit every donor, run every laboratory, transport every unit, and treat every patient, but responsibility must extend from donor safety to patient outcome.
Complete responsibility begins with the required function guiding the order. Each handoff preserves the donation, sample, storage history, and patient identity. Outcome feedback must reach the originating condition and a participant with the material means to change it.
Three questions bring the chain together:
- Which biological function does this patient need, and can the need be safely prevented, treated, or reduced without a donor component?
- Can this bag's identity, tests, processing, and storage history be connected to the patient and then to the observed outcome?
- If the component or process fails, can the chain reach related units, the originating condition, and the participant able to prevent recurrence?
The blood supply chain succeeds only when a functional component and reliable knowledge about it arrive together. Donation volume matters, but complete responsibility lies in preserving the donor, the material, the identity, the clinical purpose, and the feedback needed to protect the next patient.
Inside CompanyGraph
Explore the blood services, testing operations, logistics providers, hospital systems, and regulatory relationships that connect donors to transfusion inside CompanyGraph.